Arvinas reports Phase 1 ARV-102 shows >50% LRRK2 degradation in CSF in Parkinson's patients

ARVINAS, INC.

ARV-102 achieved approximately 50% or greater LRRK2 reduction in CSF across all doses (20–80 mg) by day 14, maintained through day 28.
Treatment was well tolerated; all adverse events were mild, with no serious adverse events, discontinuations, or deaths.
Endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB) were reduced in cerebrospinal fluid.
Mean plasma half-life of ARV-102 was 68 hours; CSF exposure increased dose-dependently indicating brain penetration.
Company plans Phase 1b trial in progressive supranuclear palsy in Q2 2026, with potential registrational trial in late 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.